Mirabilis Medica develops proprietary high-intensity focused ultrasound (HIFU) technology as a non-invasive treatment for uterine fibroids. The company is a women’s healthcare developer focused on commercializing its HIFU platform. It intends to use the new capital to advance research and development toward commercialization. Mirabilis is conducting clinical studies outside of the United States. The company was founded in 2004 and is led by newly appointed CEO Jens U. Quistgaard, a medical device entrepreneur. The recent financing activity reflects efforts to fund ongoing R&D and clinical progress.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2013